- Home
- ACET vs COEP Comparison
ACET vs COEP Comparison
Compare ACET & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | COEP |
|---|---|---|
| Founded | 1947 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 72.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | COEP |
|---|---|---|
| Price | $7.24 | $11.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $65.33 | N/A |
| AVG Volume (30 Days) | ★ 130.1K | 32.8K |
| Earning Date | 06-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $6.32 |
| 52 Week High | $9.05 | $21.41 |
Technical Indicators
Market Signals| Indicator | ACET | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 45.69 |
| Support Level | $6.54 | $10.98 |
| Resistance Level | $8.46 | $13.23 |
| Average True Range (ATR) | 0.48 | 0.94 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 37.93 | 41.06 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.